Navigation Links
BioMS Medical's relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board

Toronto Stock Exchange Symbol: MS

EDMONTON, Nov. 7 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's phase II MINDSET-01 trial of MBP8298 in patients with relapsing-remitting MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the second of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

MINDSET-01 Trial


The MINDSET-01 phase II, double-blind, placebo-controlled trial is designed to evaluate the safety and efficacy of MBP8298 in patients with relapsing-remitting MS. The fifteen month trial is fully enrolled with 218 patients at 24 sites in 6 countries. The objectives of the study are to demonstrate safety and efficacy of MBP8298 versus placebo as measured by relapse rate, MRI activity and disease progression.

About BioMS Medical Corp.


BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, MBP8298, is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. For further information please visit our website at

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that MBP8298 will continue to demonstrate a safety profile in ongoing and future clinical trials; and that BioMS Medical Corp. will complete the respective clinical trials within the timelines communicated in this release. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE BioMS Medical Corp.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Amnis Announces the Release of Multiple Upgrades to the ImageStream(R) System
5. Phase 2 Data Show Daclizumab Significantly Reduced Multiple Sclerosis Lesions in Patients Receiving Interferon Beta Therapy
6. Bioponic Phytoceuticals to Roll Out Multiple Products to 1,000 Major Health Food Stores in the Western United States
7. Actelion Announces Multiple Presentations on Tracleer(R) and the REVEAL Registry at CHEST 2007
8. Video: New Survey Finds Technology Plays a Critical Role in Lives of People with Multiple Sclerosis, Yet Many Are Not Using it to Overcome Disease-Related Challenges
9. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
(Date:10/9/2015)... ... 09, 2015 , ... From blood to food to medicine, ... from their surroundings for research, diagnostics, and cell therapy—also known as cell sorting—can ... Arbor-based startup Akadeum Life Sciences is developing a radically new product ...
(Date:10/8/2015)... 8, 2015   Intrexon Corporation (NYSE: ... the appointment of Joseph L. Vaillancourt as ... Nir Nimrodi who continues in his role as ... endeavors to generate sustainable, biologically based solutions to environmental ... he held a variety of key roles including, Vice ...
(Date:10/8/2015)... 8, 2015  ATCC, the premier global biological materials ... been selected by The Michael J. Fox Foundation for ... academic, pharmaceutical, and biotechnology organizations committed to speed a ... United States , and more than 5 million ... United States , and more than 5 million ...
(Date:10/8/2015)... 8, 2015 . ... --> Goldman Small Cap Research, a stock ... and microcap sectors, announced today that it has ... Biotech, Inc. (OTCQB - PMCB), a publicly traded, ... preparing treatments for cancer and diabetes. To view ...
Breaking Biology Technology:
(Date:9/30/2015)... , Sept. 30, 2015  With nearly 300,000 ... number of new SCIs estimated to reach 12,500 annually, ... Southern California Resource Services for Independent Living (SCRS-IL) ... in California opening doors to ... of programs and services, notably assistive technology services and ...
(Date:9/29/2015)... SUNNYVALE, Calif. , Sept. 29, 2015 ... technology improves employee productivity while also saving energy ... features such as Low Power Active Mode and embedded ... workplace transformation Fujitsu today shows that ... of new and refreshed models to its enterprise desktop ...
(Date:9/28/2015)... 2015  The monitoring of vital signs, such ... is an essential component of patient assessment. Changes ... in a patient,s condition. However, in general care ... taken during routine observation rounds only once every ... between these observation rounds, the warning signs can ...
Breaking Biology News(10 mins):